These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18195113)

  • 41. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
    Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era.
    Lee MS; Pessegueiro A; Zimmer R; Jurewitz D; Tobis J
    J Invasive Cardiol; 2008 Aug; 20(8):401-3. PubMed ID: 18688064
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of drug-eluting stents in venous coronary artery bypass grafts.
    Hernandez-Antolín R; Alfonso F; Jimenez P
    EuroIntervention; 2009 May; 5 Suppl D():D51-7. PubMed ID: 19736072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?
    Brilakis ES; Berger PB
    Catheter Cardiovasc Interv; 2008 Nov; 72(6):815-8. PubMed ID: 19006238
    [No Abstract]   [Full Text] [Related]  

  • 47. Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients.
    Flores-Ríos X; Marzoa-Rivas R; Abugattás-de Torres JP; Piñón-Esteban P; Aldama-López G; Salgado-Fernández J; Calviño-Santos R; Vázquez-Rodríguez JM; Vázquez-González N; Castro-Beiras A
    Am Heart J; 2008 Apr; 155(4):648-53. PubMed ID: 18371471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular basis of restenosis and drug-eluting stents.
    Costa MA; Simon DI
    Circulation; 2005 May; 111(17):2257-73. PubMed ID: 15867193
    [No Abstract]   [Full Text] [Related]  

  • 50. Commentary: vertebral ostium stenting: unsolved puzzle.
    Lin YH; Kao HL
    J Endovasc Ther; 2010 Apr; 17(2):241-2. PubMed ID: 20426647
    [No Abstract]   [Full Text] [Related]  

  • 51. Images in cardiology. Complete fracture of a right ventricle to pulmonary artery shunt.
    Murugan SJ; Dickinson DF; Gibbs JL
    Heart; 2005 Nov; 91(11):1441. PubMed ID: 16230444
    [No Abstract]   [Full Text] [Related]  

  • 52. [Drug-eluting stents: breakthrough or time bomb].
    Lüscher TF; Silber S
    Herz; 2007 Jun; 32(4):265-7. PubMed ID: 17607531
    [No Abstract]   [Full Text] [Related]  

  • 53. [Reduced blood pressure and myocardial infarction. Does therapy increase the risk of coronary disease?].
    Berglund G
    Lakartidningen; 1993 Sep; 90(36):2955-7. PubMed ID: 8366723
    [No Abstract]   [Full Text] [Related]  

  • 54. Through a glass, darkly.
    Block PC
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):330-1. PubMed ID: 12410509
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of Cumulative Meta-analysis of Rare Events as a Tool for Clinical Trials Safety Monitoring.
    Siontis GCM; Nikolakopoulou A; Efthimiou O; Räber L; Windecker S; Jüni P
    JAMA Netw Open; 2020 Sep; 3(9):e2015031. PubMed ID: 32886118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coming close and then pulling away.
    Holmes DR
    Eur Heart J; 2007 Jun; 28(11):1275-6. PubMed ID: 17493941
    [No Abstract]   [Full Text] [Related]  

  • 57. Lost contact with vessel wall, signed contract with stent thrombosis?
    Cassese S; Tada T; Kastrati A
    Eur Heart J; 2012 Jun; 33(11):1305-8. PubMed ID: 22374718
    [No Abstract]   [Full Text] [Related]  

  • 58. Myocardial infarction, viral infection, and the cytoskeleton final common pathways of a common disease?
    Towbin JA; Vatta M
    J Am Coll Cardiol; 2007 Dec; 50(23):2215-7. PubMed ID: 18061068
    [No Abstract]   [Full Text] [Related]  

  • 59. Is this the swan song of endovascular brachytherapy?
    Wilson JF
    Radiother Oncol; 2007 May; 83(2):214. PubMed ID: 17395325
    [No Abstract]   [Full Text] [Related]  

  • 60. Is this the swan song of endovascular brachytherapy?
    Van Limbergen E; Trepuraneni P
    Radiother Oncol; 2007 Jan; 82(1):1-4. PubMed ID: 17184863
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.